Sodium valproate in psychiatric practice: time for a change in perception.

Br J Psychiatry

Professor of Clinical Psychiatry and Honorary Consultant Psychiatrist, Centre for Clinical Brain Sciences, Division of Psychiatry, University of Edinburgh, Royal Edinburgh Hospital, Morningside Park, Edinburgh EH10 5HF, UK. Email:

Published: September 2019

Unlabelled: Sodium valproate and related preparations have recently undergone regulatory review following concern about effects on the unborn child and doctors' failure to communicate risk. The issues are wider. Valproate is overused in psychiatry based on the false perception that 'ease' of use equates to better safety than alternatives. Valproic acid can disrupt fundamental physiological processes, the consequences of which are poorly understood and little discussed in the psychiatric literature. Valproate may be useful in a small number of patients with bipolar disorder but current prescribing patterns are unjustified. Perception needs to change.

Declaration Of Interest: D.C.O. is psychiatric commissioner on the Commission on Human Medicines and a member of the European Medicines Agency's Scientific Advisory Group on Psychiatry. He chaired the European Medicines Agency's review of the psychiatric use of valproate in pregnancy and women of childbearing potential.

Download full-text PDF

Source
http://dx.doi.org/10.1192/bjp.2019.137DOI Listing

Publication Analysis

Top Keywords

sodium valproate
8
european medicines
8
medicines agency's
8
psychiatric
4
valproate psychiatric
4
psychiatric practice
4
practice time
4
time change
4
change perception
4
perception unlabelled
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!